msrinvest’s details
| symbol | subject | date & time | rating |
|
|
That is one of the more stupid things anyone has said on this board. A profit is a profit regardelss of what you did to make that happen. Clearly, selling the water business was a good move. You don't keep non-performing assets just becaus... |
5/14/2013 1:27:37 PM |
2 |
|
|
NUVO RESEARCH TO COMPLETE SHARE CONSOLIDATIONMississauga, Ontario, Canada – May 7, 2013 – Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfo... |
5/7/2013 8:54:02 AM |
|
|
|
Appears to be a call scheduled for May 2nd to present Q1 results. Call in information is on the Nuvo website. |
4/22/2013 1:50:27 PM |
4 |
|
|
I am shocked to see this stock at .45 cents. Even given that efficacy results may not be coming until 4th quarter and that the chances of success may be 50-50, why are people selling at these prices? There are other catalysts before 4th quarter... |
4/12/2013 10:55:20 AM |
4 |
|
|
The Covidien problem is much bigger than 12 months of lost Pennsaid 2% royalties, which may or may not have been materially different from original Pennsaid 2% royalties sold over the same period. The bigger problem is that Covidien did not do a... |
4/9/2013 9:27:37 AM |
1 |
|
|
Sorry, the 2012 sales number for Voltaren wasn't $80M but rather $117M. Need2stockup, the numbers you quoted were for all of Endo which includes sales of a number of other drugs, Lidoderm being the biggest of the bunch. |
3/12/2013 9:02:33 PM |
|
|
|
You should also review the Endo financials for discussions of Lidoderm and the Lidoderm generic that Watson is coming out with in September 2013. This is where Synera should be competing and where the bigger dollars can be found. |
3/12/2013 8:39:36 PM |
|
|
|
Below is taken from Endo's 2011 10K financial report. 2012 had Voltaren at about $80M mainly because of the manufacturing issues. Expectation is it will come back to 2011 levels in 2013 (see the notes section of Endo's most recent 10Q... |
3/12/2013 8:36:15 PM |
|
|
|
Thanks for your posts. Very interesting to see Lpath's valuation and a great indicator for iCo. Wondering if you could comment on what you think the effect of competition, like Lpath, will have on iCo. In reading the posted article, it cer... |
2/21/2013 9:35:55 AM |
4 |
|
|
Oops! Right you are. Apologies. |
2/20/2013 12:28:34 PM |
3 |
|
No additional content to display.
Stockhouse.com: Taking
it to the street
